Radioligand Therapy in Lymphoma: Past, Present, and Future.

PET Clin

Division of Nuclear Medicine, University of Campinas (UNICAMP), Rua Vital Brasil 251, Campinas, 13083-888, Brazil. Electronic address:

Published: October 2024

In the1980s, radiolabeled cells helped understand the pathology of hemato-oncology. In the 1990s, preclinical trials evaluated radiolabeled immunotherapy with monoclonal antibodies (MoAbs) such as anti-CD20 agents labeled with Iodine-131 (Bexxar) or Yttrium-90 (Zevalin). Due to the safe and durable responses of radiolabeled MoAbs, the Food and Drug Administration approved these agents in the 2000s. Despite radioimmunotherapy's long journey, its application has recently decreased. This review will discuss the historical timeline of radioimmunotherapy, debate on advantages and difficulties, and explore trials. We will examine future directions of radioligand therapy in hemato-oncology, considering emerging molecules that may become the next theragnostic trend.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpet.2024.05.003DOI Listing

Publication Analysis

Top Keywords

radioligand therapy
8
therapy lymphoma
4
lymphoma future
4
future the1980s
4
the1980s radiolabeled
4
radiolabeled cells
4
cells helped
4
helped understand
4
understand pathology
4
pathology hemato-oncology
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!